Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: A case report

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Liang, Wenhua ^a,b   He, Qihua ^a,b   Chen, Ying ^a,b   Chuai, Shaokun ^c   Yin, Weiqiang ^a,b   Wang, Wei ^a,b   Peng, Guilin ^a,b   Zhou, Caicun ^a,b,d   He, Jianxing ^a,b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c Burning Rock Biotech   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Co existence; EGFR mutation; EML4 ALK rearrangement; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BEVACIZUMAB; BRIGATINIB; CIRCULATING TUMOR DNA; CRIZOTINIB; DNA; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; HY 15772; HYBRID PROTEIN; METHYLPREDNISOLONE; OSIMERTINIB; PEMETREXED; PROTEIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BLEEDING; BRAIN METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; DRUG RESPONSE; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOMICS; GENOTYPE; HUMAN; LIVER BIOPSY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; METASTASIS; NON SMALL CELL LUNG CANCER; SPINE METASTASIS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PYRAZOLES; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84957052714     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2088-5     Document Type: Article

References (16)

1. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105(9):595-605.
2. Qian H, Gao F, Wang H, Ma F. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lungcancer: a meta-analysis of clinical trials. BMC Cancer. 2014;14:683.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM. Non-Small Cell Lung Cancer. V5.2015. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed March; 2015.
4. Gray J, Haura E. Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res. 2014;3(6):360-2.
5. Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17.
6. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31(8):1039-49.
7. Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, et al. Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. Clin Chem 2015. [Epub ahead of print].
8. O'Brien CP, Taylor SE, O'Leary JJ, Finn SP. Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer. 2014;83(3):309-15.
9. Xu CW, Cai XY, Shao Y, Li Y, Shi MW, Zhang LY, et al. A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: a case report and literature review. Mol Med Rep. 2015;12(3):4370-5.
10. Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. 2014;20(5):1383-92.
11. Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013;79(1):33-9.
12. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990-8.
13. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108-12.
14. Zhao N, Zheng SY, Yang JJ, Zhang XC, Xie Z, Xie B, et al. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review. Clin Lung Cancer. 2015;16(2):e5-9.
15. Alì G, Chella A, Lupi C, Proietti A, Niccoli C, Boldrini L, et al. Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: a case report. Oncol Lett. 2015;9(4):1537-40.
16. Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W 3rd, et al. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci U S A. 1991;88(9):3847-51.